Premium class tickets are far more profitable for airlines than coach, which is why they’re all working feverishly to win ...
Your approach to risk management and regulatory compliance is probably broken. Not because you don’t have capable people ...
Biosciences to launch $40M Series A at JPM 2026, advancing CS-0003 mucosal-immune therapies for GI SSI and the GB platform.
Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollmentCHARLESTOWN, Mass., Jan. 12 ...
Katie joins Leeds Equity with over seven years of private equity and investment banking experience, most recently as an Associate at Vista Equity Partners. Prior to Vista Equity Partners, Katie was an ...
Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –– Recruitment ongoing for ...
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today highlighted the ...
Another perk bites the dust! Airlines are notorious for nickel-and-diming everything from bags to meals to drinks, and you ...
Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...
BioMed Realty, the largest privately-owned operator of real estate for the life science and technology industries, and ...
Features include fast charging, triple-screen infotainment, and adjustable rear seating for practicality.
Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback